These are not always included in the monthly price and can add $100$300 or more depending on the provider
According to the STEP 1 trial published in the New England Journal of Medicine, patients taking semaglutide 2.4 mg (Wegovy) achieved approximately: 3% to 5% body weight loss by week 12 10% to 12% body weight loss by week 28 15% to 17% body weight loss by week 68 (maximum effect) These figures represent average outcomes in clinical trials
If you are taking insulin and starting a GLP-1 receptor agonist, your insulin dose may need to be reduced gradually under medical supervision
However, fewer side effects does not automatically mean equally effective results. Label-guided slow titration already exists to balance both
De Leon DD, Farzad C, Crutchlow MF, Brestelli J, Tobias J, Kaestner KH, and Stoffers DA